Risk assessment of new psychoactive substances - EMCDDA - Europa

D1.1.D1.2.Animal dataHere, data regarding acute toxicity studies in animals, as well as safetypharmacology data can be mentioned, if available.Human dataRelevant acute adverse effects, both physical and psychological, reportedby users, admissions to emergency rooms and reports on overdosesor fatal intoxications can be included. However, side effects noted inlaboratory studies can also be included, if available.D2. Chronic health effectsD2.1.D2.2.Animal dataChronic studies in animals are usually not available for new psychoactivesubstances. However, if available, any data on repeated dose toxicity,genotoxicity, carcinogenicity, reproductive toxicity or other forms oftoxicity, including neurotoxicity can be mentioned in this section.Human dataFor new psychoactive substances, long-term data on health effects inhumans will usually be limited, if available at all. A description basedon reports from users may be included, but also epidemiological data,if there is any. For chronic effects, the causal link with the use of the newpsychoactive substance will in most cases be very difficult to establish,since numerous confounding factors will also be present. Both aspects ofphysical and psychological well-being should be considered.D3. Factors affecting public health risksOne factor of utmost importance affecting any potential health impactat population level is the prevalence of use. This aspect is described inSection C. Other factors influencing the impact on public health are:D3.1.D3.2.Availability and quality of the new psychoactive substance on the market(purity, adulterants, etc.).Availability of information, degree of knowledge and perceptionsamongst users concerning the psychoactive substance and its effects.51